ArticleSexual medicine2025
NFKB1-targeted metabolites as novel therapeutic approaches for erectile dysfunction: evidence from gut microbiota network pharmacology and machine learning.
Article in Sexual medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growing evidence suggests that alterations in the gut microbiota may contribute to the pathogenesis of erectile dysfunction (ED). Aim: To investigate the potential causal relationship between specific gut microbial taxa and ED, identify key microbial metabolites and their associated target genes, and evaluate their therapeutic potential through computational drug screening. Methods: Genome-wide association study (GWAS) summary statistics for gut microbiota and ED were obtained from the MiBioGen, IEU OpenGWAS, and FinnGen databases. Mendelian randomization (MR) analysis was performed using the TwoSampleMR package to assess potential causal relationships. A microbiota-metabolite-target gene network was constructed using data from GutMGene, Super-PRED, and GeneCards databases to explore the microbiota-host interaction axis. The DeepPurpose machine learning framework was utilized to predict drug-target binding affinities, and top-ranking drug-gene pairs were validated by molecular docking to assess binding free energies and confirm interaction stability. Outcomes: The study aimed to identify specific gut microbiota, metabolites, and target genes associated with ED and evaluate their therapeutic potential. Results: MR analysis revealed a negative association between ED and the gut microbial genera Clinical Implications: These findings suggest that gut microbiota and their metabolites could serve as potential therapeutic targets for ED interventions. Strengths and Limitations: The study provides novel insights into the gut microbiota-ED relationship by integrating multi-omics data and advanced computational methods. However, validation in preclinical or clinical studies is needed to translate these findings into therapeutic applications. Conclusion: Specific gut microbiota, through metabolites and associated target genes, may influence the onset of ED. These findings highlight potential therapeutic targets and provide a basis for future interventions in ED treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.